Candel Therapeutics (CADL) Share-based Compensation (2020 - 2025)

Candel Therapeutics has disclosed Share-based Compensation across 6 years of filings, most recently posting $1.3 million for Q4 2025.

• Share-based Compensation for Q4 2025 came in at $1.3 million, up 3.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.8 million (down 28.14% YoY), and the FY2025 annual result was $3.8 million, down 28.14% from the prior year.
• Share-based Compensation came in at $1.3 million for Q4 2025 at Candel Therapeutics, up from $1.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.9 million in Q3 2021 to a low of -$446000.0 in Q4 2021.
• The 5-year median for Share-based Compensation is $841000.0 (2022), against an average of $874500.0.
• Peak annual rise in Share-based Compensation reached 2200.0% in 2021, while the deepest fall reached 125.44% in 2021.
• Candel Therapeutics' Share-based Compensation stood at -$446000.0 in 2021, then jumped by 242.15% to $634000.0 in 2022, then jumped by 48.11% to $939000.0 in 2023, then soared by 32.48% to $1.2 million in 2024, then climbed by 3.7% to $1.3 million in 2025.
• The last three Share-based Compensation figures came in at $1.3 million (Q4 2025), $1.2 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.